Prevalence of intellectual disability: A meta-analysis of population-based studies

24 Feb

Autism prevalence gets a lot of discussion here and elsewhere on blogs. But what about other prevalence numbers? Say, for intellectual disability? This is important on its own in this discussion. Intellectual disability (ID) is more common amongst autistics than in the general population. In addition, it is worth noting that even with something like ID, prevalence values vary.

In general, the prevalence of ID is about 1%. Similar to autism prevalence. The prevalence of ID varies by country and by income, and by age.

Prevalence of intellectual disability: A meta-analysis of population-based studies

Abstract

Intellectual disability is an extremely stigmatizing condition and involves utilization of large public health resources, but most data about its burden is based on studies conducted in developed countries. The aim of this meta-analysis was to collate data from published literature and estimate the prevalence of intellectual disability across all such studies. The review includes studies published between 1980 and 2009, and includes data from populations that provided an overall estimate of the prevalence of intellectual disability. Meta-analysis was done using random effects to account for heterogeneity. Sub-group analyses were also done. The prevalence of intellectual disability across all 52 studies included in the meta-analysis was 10.37/1000 population. The estimates varied according to income group of the country of origin, the age-group of the study population, and study design. The highest rates were seen in countries from low- and middle income countries. Studies based on identification of cases by using psychological assessments or scales showed higher prevalence compared to those using standard diagnostic systems and disability instruments. Prevalence was higher among studies based on children/adolescents, compared to those on adults. Higher prevalence in low and middle income group countries is of concern given the limitations in available resources in such countries to manage intellectual disability. The importance of using standardized diagnostic systems to correctly estimate the burden is underlined. The public health and research implications of this meta-analysis have been discussed.
Research highlights

The prevalence of intellectual disability across the world is around 1%. The prevalence is almost two times more in low and middle income countries compared to high income countries. Highest prevalence was seen in child and adolescent population. Using standardized diagnostic instruments and disability measurements leads to lower estimates compared to simple psychological assessment tools even if confirmed by clinicians.

emphasis added.

As with autism prevalence, we need to look at these numbers in context: the culture of the country, the methods used, diagnostic criteria.

Whenever you hear someone say something like “One in 110 children born today will have autism” you are listening to someone who doesn’t really understand the “estimate” part of prevalence estimate.

Brief Report: Prevalence of Pervasive Developmental Disorder in Brazil: A Pilot Study

24 Feb

Real data on autism prevalence around the world is scant. Many countries do not track accurately (including the US) and few countries have reported on autism prevalence.

So, while this is only a “pilot study”, I was intrigued to read that someone was reporting on autism prevalence in Brazil:

Brief Report: Prevalence of Pervasive Developmental Disorder in Brazil: A Pilot Study.

Paula CS, Ribeiro SH, Fombonne E, Mercadante MT.

Developmental Disorder Post Graduation Program, Mackenzie Presbyterian University, Rua da Consolação, 930. Edifício 38 Secretaria de Pós-Graduação em Distúrbios do Desenvolvimento, São Paulo, SP, 01302-907, Brazil, csilvestrep09@gmail.com.
Abstract

This pilot study presents preliminary results concerning the prevalence of Pervasive Developmental Disorder (PDD) in South America. It was a three-phase study conducted in a typical town in Southeast Brazil. Case definition was based in a combination of standardized instruments and clinical evaluations by experts. The prevalence of PDD was 27.2/10,000 (95% CI: 17.6-36.8) and some hypotheses were raised to explain this low frequency. Clinical findings of PDD cases were consistent with previous data, such as, male preponderance, more children diagnosed with PDD-NOS than with autistic disorder, and half of them born from older mothers. Moreover, the study raised concerns about treatment of cases, because identification of PDD had been late and access to services has been very limited.

The prevalence is low: about 0.27% for all PDD’s. About 1/4 that of the US or the UK.

Just in this year (2011), 4 other papers have come out on autism prevalence:

Denmark and Australia: 0.685% and 0.51%, respectively.

Autism prevalence varies by race, even within a single US municipality (Atlanta). In the San Francisco Bay area, autism prevalence is about 0.47%, and again varies with race/ethnicity. Yes, the San Francisco bay area has a prevalence about 1/2 the national average.

While more of a review, this paper discusses how autism prevalence rates vary by country

Autism prevalence estimates vary. They vary with time, they vary with place, they vary with ethnicity, they vary with socio-economic status. I don’t think it is hopeless to try to pull causation inferences from prevalence data, even administrative prevalence data like education data or the CDDS data. It is hard though. There are obviously a number of factors at play. Many social factors included. And that makes it really hard to interpret what all these data mean.

As a final aside, for those trying to work these latest data from Brazil into the “vaccine hypothesis”, the vaccine schedule for Brazil is here. They have a lot of vaccines, including the birth dose of HepB and thimerosal containing vaccines. The low prevalence in this pilot study do not support the hypothesis.

Will You Let Politicians Sacrifice Your Child?

23 Feb

Will You Let Politicians Sacrifice Your Child? is the title of an article by Howard Margolis.

The piece brings up some very good points and is well worth the read. In the US, we are facing cutbacks on support for the disabled. The time to fight about this is now.

Unless parents of children with special needs do something quickly, unless they start to deal with budgetary problems and stop buying into the false belief that this country is broke, their children will be sacrificed on the unfounded altars of “tax cuts for the rich” and “austerity” for everyone else.

There is at least one point I disagree with, but the idea that we have the money to continue the levels of support we have (which are not high), is a good one:

This country is rich. It has plenty of money. If it didn’t, it couldn’t have given huge tax cuts to the upper 1% of wealthy (who get about 24% of America’s annual income). If it didn’t, it couldn’t give politicians such rich pensions. If it didn’t, corporations couldn’t get away with paying little or no taxes. If it didn’t, hedge fund managers wouldn’t have a 15% tax cap on most of their income. If it didn’t, Wall Street and banker bonuses wouldn’t be astronomical. If it didn’t, Albert Pujols couldn’t hold out for $300,000,000. If it didn’t, in 2010 the U. S. Chamber of Commerce couldn’t have spent more than $70,000,000 to defeat the Democrats.

He quotes an earlier piece he wrote, and I repeat it here:

Ignore bumper sticker phrases like ‘reduce taxes,’ ‘higher standards,’ ‘throw the bums out.’ These are usually shorthand phrases for inflaming anger or bigotry and gaining political power, not phrases for strengthening knowledge or insight and improving lives…. Instead, read about and study policies that will help your children and then become politically active in supporting them. Keep holding politicians accountable: keep asking them questions, keep examining their votes, keep examining the bills they offer, keep calling them, keep withholding support for those whose actions don’t immediately help your child and other children, keep supporting those whose actions do, join and actively support organizations that support your views. Consider running for office so you can institute and support policies that help children. Learn, learn, learn. And share your learning. Keep writing to newspapers and magazines and blogs. Call radio shows. Let them know what you think and why: provide compelling facts and logic, not bitterness and bluster. Help schools to get the resources they need to help your child and all children; then keep holding the schools accountable for their actions. If they have the resources, they should have the accountability. Do the same for state agencies that are supposed to serve adults with disabilities…. And so you must advocate hard for your child’s needs, for the needs of all children. And you must keep advocating: respectfully, forcefully, intelligently, knowledgeably, and persistently.

State budgets, local budgets, federal budgets, school budgets–they are all facing a decline due to lost revenue. That just means that now is the time to fight.

Again, read the full piece , it’s worth it.

Social determinants of state variation in special education participation among preschoolers with developmental delays and disabilities

23 Feb

Sometimes things we think should be constant aren’t. This is very clear with autism, where “rates” vary with time and geography. Anyone have a reason why the autism prevalence in Alabama is almost 1/2 that of New Jersey?

These sorts of issues intrigue me. So when a paper showed up recently in one of my pubmed searches, I had to take a look.

Social determinants of state variation in special education participation among preschoolers with developmental delays and disabilities

Children with developmental disabilities are at risk for secondary complications and lower academic performance, which contributes to lower health and well-being and may be ameliorated by access to special education services. This paper examines state variability in preschool special education participation among a United States population-based cohort with parent-reported developmental delays and disabilities. Analyses explore the extent to which observed variability can be explained by state socio-economic attributes and special education policy and funding. Rates of special education varied significantly across states and were highest in states with least income inequality and lowest in states with most income inequality. Place variation in preschool special education participation stems, in part, from child characteristics, but to a larger extent, from state socio-economic attributes.

Preschool programs for special ed kids have a wide variability in the attendance rates. Here’s a map that shows this variability (click to enlarge):



State differences in preschool special education participation among a national sample of 3–5 year olds (n=2435) with developmental delays and disabilities.

Being “non poor” or having a more “severe” condition is associated with attending special ed preschools. Where the funding comes from (state vs. local) has an impact on how many kids attend special ed preschool.

I don’t consider this study to be the most rigorous possible, but it does give us a view that social factors can have a large impact on issues such as special education participation.

Age of Autism have a good old cry on Twitter

22 Feb

Back story: as Sully blogged the other day an American political cartoon strip had a bit of a dig at the anti-vaccine brigade. This provoked the following response from Age of Autism:

Yeah, thats right, Age of Autism truly see themselves as a victimised minority group. No really. They do. They’re putting themselves on the same footing as every Suffragette, every victim of Apartheid, every disabled activist and every poverty stricken member of a developing country thats ever lived.

Age of Autism have a slogan ‘the bull stops here’

and they’re absolutely right – thats exactly where the bull stops. In fact, it not only stops, it takes its slippers off, puts its feet up and stays for ever.

Age of Autism, you really need to get a grip. Maybe a name change might help (click for bigger).

Supreme Court decides Bruesewitz v. Wyeth

22 Feb

As Ken has recently written, the Supreme Court has decided on the case of Bruesewitz v. Wyeth. This is not an autism case, but involves the rights to sue a vaccine manufacturer for design defect claims outside of the court system set up 25 years ago in the Vaccine Act.

Justice Scalia wrote the decision, with Justice Breyer submitting a concurring statement and Justice Sotomayor writing the dissent. It was a 6-2 decision, with Justices Sotomayor and Ginsberg dissenting and Justice Kagan not participating.

The parents had already brought their case to the Court of Federal Claims (“vaccine court”), which ruled against them. They did not accept the ruling and took their case to other courts. Eventually landing in the Supreme Court of the United States (SCOTUS). The U.S. Supreme court is an appeals court. As such, this case is an appeal of a lower court (Court of Appeals) ruling. The Supreme Court ruled:

For the foregoing reasons, we hold that the National Childhood Vaccine Injury Act preempts all design-defect claims against vaccine manufacturers brought by plaintiffs who seek compensation for injury or death caused by vaccine side effects. The judgment of the Court of Appeals is affirmed.

The Court summarized a major part of the claim as:

Their complaint alleged (as relevant here) that defective design of Lederle’s DTP vaccine caused Hannah’s disabilities, and that Lederle was subject to strict liability, and liability for negligent design, under Pennsylvania common law.

The parents had argued that they could sue under a “design defect” argument, and “strict liability“.

Design defects are defined as:

In the law of products liability, a design defect exists when a defect is inherent in the design of the product itself. In a products liability case, a plaintiff can only establish a design defect exists when he proves there is hypothetical alternative design that would be safer that the original design, as economically feasible as the original design, and as practical as the original design, retaining the primary purpose behind the original design despite the changes made.

Strict liability” “…applies when a defective product for which an appropriate defendant holds responsibility causes injury to an appropriate plaintiff.”

They claimed that the manufacturer of the vaccine can be sued because a safer vaccine could have been produced and avoided the injury.

Note that in this SCOTUS case, they aren’t arguing the facts of the case–whether the vaccine caused injury–just whether they had the right to sue in a civil court based on the “design defect” claim. SCOTUS did not rule one way or another on the injury claim that was rejected by the Court of Federal Claims.

As to the liability issue, Federal law states:

“[n]o vaccine manufacturer shall be liable in a civil action for damages arising from a vaccine-related injury or death associated with the administration of a vaccine after October 1, 1988, if the injury or death resulted from side-effects that were unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings.”

Much language is spent on the meaning of the “if” clause and the “even-though” clause. Many words to discuss a short paragraph. One which I thought was quite clear. But I’m not an attorney.

In the Court’s discussion is this paragraph:

Design defects do not merit a single mention in the Act or in Food and Drug Administration regulations that pervasively regulate the drug manufacturing process. This lack of guidance for design defects, combined with the extensive guidance for the two liability grounds specifically mentioned in the Act, strongly suggests that design defects were not mentioned because they are not a basis for liability. The Act’s mandates lead to the same conclusion. It provides for federal agency improvement of vaccine design and for federally prescribed compensation,which are other means for achieving the two beneficial effects of design-defect torts—prompting the development of improved designs, and providing compensation for inflicted injuries.

Design defects are just not part of the equation in the Vaccine Act, and the Court decided that this is because the lawmakers intended it that way.

Does this mean that Americans have no recourse in vaccine injury claims? The claim has already been made, even as I was writing this post:

According to vaccine safety advocate Louise Kuo Habakus, “The Court is telling parents that they’re on their own. Parents know that 4 out of 5 cases of vaccine injury do not get compensation in the misnamed Vaccine Injury Compensation Program. The Supreme Court has slammed the courthouse doors shut.”

“Parents know that 4 out of 5 cases of vaccine injury do not get compensation in the misnamed Vaccine Injury Compensation Program.”

What a statement. I’ve never heard this statistic before. I guess I’m not a “parent” by the definitions of the self-styled “vaccine-safety” community. Or, maybe, just perhaps…the statistic is made up or manipulated and this is the time to try to get it into the national discussion.

Are the courthouse doors shut? Hardly. There is the Court of Federal Claims, which does compensate people by allowing Americans to petition the U.S. government directly. That is no small issue, by the way. Sovereign states can not be sued under normal circumstances.

Even aside from the Court of Federal Claims, is this 100% immunity from liability? I don’t believe so. Remember that phrase: “…even though the vaccine was properly prepared and was accompanied by proper directions and warnings”. What if a vaccine is not properly prepared? Or if it doesn’t have proper directions and warnings?

A legal term is used throughout the decision: “unavoidably unsafe products”. I was going to predict that this term would be used to scare people about vaccines. I can’t make that prediction, because it has already started. Again from Ms. Habakus:

Because the federal government recommends 70 doses of 16 “unavoidably unsafe” vaccines, and states compel 30-45 doses for school attendance, this issue affects all children.

Keep this in mind. Not vaccinating yourself or your child is an “unavoidably unsafe” decision. Also it is an “unavoidably unsafe” decision for others.

Justice Sotomayor wrote about “unavoidably unsafe” in her dissenting opinion, citing “… comment k of §402A of the Restatement of Torts (Second) (1963–1964)”. (comment k gets discussed much by both sides).

“Unavoidably unsafe products. There are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use. These are especially common in the field of drugs. An outstanding example is the vaccine for the Pasteur treatment of rabies, which not uncommonly leads to very serious and damaging consequences when it is injected. Since the disease itself invariably leads to a dreadful death, both the marketing and the use of the vaccine are fully justified, notwithstanding the unavoidable high degree of risk which they involve. Such a product, properly prepared, and accompanied by proper directions and warning, is not defective, nor is it unreasonably dangerous. The same is true of many other drugs, vaccines, and the like, many of which for this very reason cannot legally be sold except to physicians, or under the prescription of a physician. It is also true in particular of many new or experimental drugs as to which, because of lack of time and opportunity for sufficient medical experience, there can be no assurance of safety, or perhaps even of purity of ingredients, but such experience as there is justifies the marketing and use of the drug notwithstanding a medically recognizable risk. The seller of such products, again with the qualification that they are properly prepared and marketed, and proper warning is given, where the situation calls for it, is not to be held to strict liability for unfortunate consequences attending their use, merely because he has undertaken to supply the public with an apparently useful and desirable product, attended with a known but apparently reasonable risk.”

This is the entire point of the informed consent, by the way. If there is no chance of adverse events, there is no need to “inform” the patient about anything. I bring this up because informed consent is supposed to be a big issue for “vaccine-safety” groups.

Justice Sotomayor accuses the majority of writing a “policy driven” decision.

25Respondent notes that there are some 5,000 petitions alleging a causal link between certain vaccines and autism spectrum disordersthat are currently pending in an omnibus proceeding in the Court of Federal Claims (Vaccine Court). Brief for Respondent 56–57. Accord-ing to respondent, a ruling that §22(b)(1) does not pre-empt design defect claims could unleash a “crushing wave” of tort litigation that would bankrupt vaccine manufacturers and deplete vaccine supply. Id., at 28. This concern underlies many of the policy arguments inrespondent’s brief and appears to underlie the majority and concurring opinions in this case.

Perhaps I am naive, but I agree that such statements should not weigh into the decision. If these 5,000 petitioners have the right to sue, they should have that right.

Justice Sotomayor goes on to say:

In the absence of any empirical data, however,the prospect of an onslaught of autism-related tort litigation by claimants denied relief by the Vaccine Court seems wholly speculative.

It may be speculative, but is as good a speculation as you can get. Yes, if Bruesewitz had prevailed, there would be an onslaught of autism-related tort litigation.

Further, she states:

Trial courts, moreover, have considerable experience in efficiently handling and disposing of meritless products liability claims, and decades of tort litigation (including for design defect) in the prescription-drug context have not led to shortages in prescription drugs.

Which is a very strange statement in context. Yes, some autism-vaccine cases have been halted before they started in civil courts. But the entire basis for the Vaccine Act and the Court of Federal Claims taking on the vaccine issue is the claims that DPT was causing a huge wave of disability. A claim which was later found to be meritless, as later science showed no association. The litigation which prompted the Vaccine Act did lead to shortages and was well on its way to leaving the US without vaccine providers.

This all said, in the end it isn’t whether the court is right or wrong (as will no doubt be discussed at length in some circles). For practical purposes, what matters is that the court has decided. People are not able to take vaccine manufacturers to civil court on design defect claims.

With that and the end of the Omnibus Autism Proceeding, autism-vaccine litigation is essentially over. If some real evidence were to come forward which could make autism causation by vaccination a defensible idea, sure, cases would be heard again in the vaccine court. Until that time, legally as well as scientifically, the idea has had its day and it is time to move on.

Genetic explanation for why autism (apparently) affects more males than females

22 Feb

Firstly we should start by saying there is a strand to the debate that strongly indicates that autism in females is heavily underdiagnosed.

That said, interesting new research emerges from George Washington University.

The team basically looked at a gene implicated in autism called retinoic acid-related orphan receptor-alpha, or RORA (brains of autistic people make less of it than usual) and bathed it in two things.

Firstly they bathed human brain cells in an oestrogen mix and secondly they bathed different brain cells in DHT. The oestrogen _enhanced_ RORA production whereas the DHT _supressed_ it.

This is not to downplay the role that underdiagnosis in females very probably plays but it does show how genes affect autism directly.

Supreme court affirms 1986 Vaccine Act

22 Feb

The US Supreme Court has ruled 6-2 that pharmaceutical companies cannot be sued for a vaccine-related injury or death as long as the vaccine was properly prepared and came with directions and warnings. Associate Justice Sonia Sotomayor and Ruth Bader Ginsburg dissented. Associate Justice Elena Kagan did not participate in the case, known as Brueswitz v. Wyeth. From the Wall Street Journal:

The court ruled against parents who claimed their daughter suffers from a seizure disorder as the result of a Wyeth vaccination she received as an infant in 1992. The vaccine was discontinued in 1998.

The National Childhood Vaccine Injury Act of 1986 was enacted to reduce the potential financial liability of vaccine makers while ensuring supply. It created a no-fault arbitration process for injury claims, known as the National Vaccine Injury Compensation Program.

“Childhood vaccines are among the greatest medical breakthroughs of the last century,” said O. Marion Burton, MD, president of the American Academy of Pediatrics. The AAP was one of 22 health organizations which urged the Court to confirm that the National Childhood Vaccine Injury Compensation Act of 1986 (“Vaccine Act”) preempted design defect claims against vaccine manufacturers. “Today’s Supreme Court decision protects children by strengthening our national immunization system and ensuring that vaccines will continue to prevent the spread of infectious diseases in this country.”

The case turned on the interpretation of this paragraph in the 1986 Vaccine Act legislation:

“No vaccine manufacturer shall be liable in a civil action for damages arising from a vaccine-related injury or death associated with the administration of a vaccine after October 1, 1988, if the injury or death resulted from side effects that were unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings.”

Writing for the majority, Justice Antonin Scalia said:

The “even though” clause clarifies the word that precedes it. It delineates the preventative measures that a vaccine manufacturer must have taken for a side-effect to be considered “unavoidable” under the statute. Provided that there was proper manufacture and warning, any remaining side effects, including those resulting from design defects, are deemed to have been unavoidable. State-law design-defect claims are therefore preempted.

Get ready for the flood of fetal gene screening

21 Feb

In a recent article in Nature, Henry T. Greely, proposes that the time when prenatal genetic screening may be commonplace is closer than, well, I thought.

The world’s news media was buzzing last week after researchers showed that a blood test for mothers could detect Down’s syndrome in their fetuses[1]. Last month, two research groups independently published proof that the fetal genotype — the genetic status at a given locus — can be derived for thousands of sites from samples of fetal DNA with just a 10-millilitre blood draw from a pregnant woman[2, 3].

[1] Chiu, R. W. K. et al. Br. Med. J. doi: 10.1136/bmj.c7401 (2011).

[2] Lo, Y. M. D. et al. Sci. Transl. Med. 2, 61ra91 (2010).

[3] Fan, H. C. & Quake, S. R. Nature Precedings doi:10.1038/npre.2010.5373.1 (2010).

Until now, the main prenatal testing has been for Down Syndrome. It is not common:

Prenatal genetic testing has been clinically available since the late 1960s, but the costs, inconvenience and especially the miscarriage risks have limited its use. Each year, less than 2% of pregnant women in the United States undergo amniocentesis (in which a small amount of amniotic fluid containing fetal cells is taken for analysis) or chorionic villus sampling (CVS — in which fetal tissue is extracted from the placenta). Both procedures increase the risk of miscarriage. Until now, any given sample could be tested for only one or two conditions, typically chromosomal abnormalities such as trisomy 21, the cause of Down’s syndrome.

It is uncommon, but it is offered in high risk situations (older mothers). Since the test has been offered, the prevalence of Down Syndrome has dropped significantly. This in spite of the fact that older mothers are more common now.

Amniocentesis is obviously invasive, resulting in risk to the unborn child. But a blood draw would be a non-invasive prenatal genetic diagnosis (NIPD).

The potential of NIPD goes way beyond Rhesus screening. Two of the leading researchers in cell-free fetal DNA testing — Dennis Lo of the University of Hong Kong and Steve Quake of Stanford University in California — use different methods to analyse fetal cell-free DNA from maternal serum. Each has demonstrated the ability to detect aneuploidies — missing or extra chromosomes, such as in trisomy 21 (refs 5, 6). Last month, both researchers published proof that the fetal genotype could be derived for thousands of sites from cell-free fetal DNA2, 3 — demonstrating the possibility of using maternal blood to test for all fetal genetic traits.

The methods demonstrated are already interesting commercial firms:

Commercial firms are already interested. Sequenom in San Diego, California, is working with Lo; another, Artemis Health of Menlo Park, California, is working with Quake; and still others are also exploring the technology. For-profit development of these methods seems likely within five years, at least for chromosomal abnormalities, such as trisomy 21, and possibly for single-gene traits.

My insurance plan will pay for prenatal genetic testing, but not for genetic testing of a child. I find that thought a bit chilling.

Until now, prenatal genetic testing has been relatively uncommon. The ethics discussions have been largely academic. Important, but academic. The time for academic discussions of the ethics is drawing to a close.

Professional organizations, in medicine and in genetics, need to get involved, both in training their members about these technologies and in beginning to consider guidelines for their use, especially with regard to informed consent. Regulators, companies and consumer advocates need to be talking about pathways for assuring the safety, efficacy and quality of NIPD testing. In the United States, the Food and Drug Administration should start that process immediately. And it is time for ethics commissions, such as the US Presidential Commission for the Study of Bioethical Issues, to report on these issues.

Most importantly, we need to start conversations, between all those concerned, about the limits, if any, to place on this powerful technology. Whether we view NIPD gladly as a way to reduce human suffering, warily as a step towards a eugenic dystopia, or as a mix of both, we should agree that the better we prepare, the more likely we are to avoid the worst misuses of this potentially transformative technology.

What disabilities will eventually have genetic screening possible? How will we as a society take on the ethical challenges? If the drop in Down Syndrome is any indication, I think there is reason to take this discussion very seriously. Now.

Garry Trudeau of Doonesbury takes on Jenny McCarthy and the “bogus vaccine-autism link”

20 Feb

One of the big problems with the media has been their willingness to give the vaccine-induced-autism-epidemic idea far more wight than it deserved. While the science has been very one sided against the theories presented, the media usually puts out “he said/she said” type stories. You know the type. A new study will come out. A news story will be produced. They will open with people talking about the increasing numbers of people diagnosed with autism and the belief in the vaccine link in some groups. The scientists for the new study will be interviewed. And then the story will end with parents saying, “but I know the link is real”. It was a world of false balance.

That world has changed, at least for now. Sure not everywhere, but the media and the public’s perception of vaccines and autism has changed.

Case in point: the comic strip “Doonesbury”. For about 40 years Gary Trudeau has had his finger on the pulse of American society. He has been a harsh critic of political figures and popular culture figures (many papers have placed his comic on the opinion or editorial pages).

Here are a couple of panels from today’s strip (click to enlarge). Boopsie, former cheerleader and Playboy playmate, is discussing Jenny McCarthy:

The full strip can be found at Doonesbury.com.

The vaccine-causation idea has only survived through the media and public relations. The science never really supported the hypotheses. Jenny McCarthy rode the vaccine story back into the public’s eye, and appears to be trying to jump ship before it drags her back down. If today’s Doonesbury is any indication, she may have waited too long. She could do a lot of good by making a public statement distancing herself from the junk science and PR campaigns that created the image of a vaccine-induced-epidemic. It wouldn’t make up for all the damage she caused, but it would be better than having her publicity people beg the Colbert show to not be harsh on her, while she was at the same time writing pieces supporting the junk scientists for the Huffington Post.

When Doonesbury is calling you out for promoting a “bogus vaccine-autism link” and for causing real harm to preventive health care, you’ve lost public support. You can either try to stay low and ride it out, or do the right thing and repair some of the damage you’ve caused. The choice is yours, Ms. McCarthy.